SEARCH

SEARCH BY CITATION

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

FilenameFormatSizeDescription
emmm201202341.reviewer_comments.pdfPDF document389KReview Process File
emmm201202341-sm-0002-SupData-S1.xlsxExcel 2007 spreadsheet55KSupporting Data
emmm201202341-sm-0003-SupFigs-S1.pdfPDF document4436K

Figure S1. (A) Inhibition of cell proliferation upon FBXO28 depletion.

Figure S2. (A) FBXO28 protein is evolutionary conserved.

Figure S3. (A) Downregulation of MYC target genes upon depletion of FBXO28 by siRNA transfection in HCT116 cells.

Figure S4. (A) MCF-7 cell extracts cotransfected with the indicated expression constructs were immunoprecipitated with FLAG antibodies followed by immunoblotting with MYC (N262) antibody as indicated.

Figure S5. (A) Luciferase assay in HeLa cells transfected with the salt-induced kinase (SIK) gene luciferase reporter for 48 h, in combination with the indicated expression constructs or siRNAs.

Figure S6. (A) P53−/− MEF cells were embedded in soft-agar medium after co-transduction with shFBXO28 vectors or a shRNA-GFP control vector and MYC, as indicated.

Figure S7. (A) IB analysis was performed in a panel of primary breast tumor specimens (cohort 1).

Table S1. Top ranked F-box genes that reduced cell proliferation in KPL4 cells upon RNAi in the functional screen shown in Fig 1B.

Table S2. FBXO28 is overexpressed in primary breast cancer.

Table S3. FBXO28 expression in human breast cancer correlates with a gene set associated with MYC and p300 activity as determined by ChIP-seq.

Table S4. Excel spread sheet.

Table S5A. Correlation between clinicopathological characteristics of breast cancer patients with low (<25%) and high (>25%) nuclear fraction (NF) of phosphorylated FBXO28 (Cohort 2, N = 144).

Table S5B. Cox univariate analysis for overall survival (OS) and breast-cancer specific survival (BCSS) according to the nuclear fraction (NF) of phosphorylated FBXO28 and other established clinocpathological parameters.

Table S5B. Cox univariate analysis for overall survival (OS) and breast-cancer specific survival (BCSS) according to the nuclear fraction (NF) of phosphorylated FBXO28 and other established clinocpathological parameters.

Table S5C. Cox multivariate analysis for overall survival (OS) and breast cancer specific survival (BCSS) according to the nuclear fraction (NF) of phosphorylated FBXO28 (Cohort 2, N = 144).

Table S6A. Correlation between clinicopathological characteristics and FBXO28 protein phosphorylation and expression in the nucleus (Cohort 3, N = 498).

Table S6B. Cox multivariate analysis for overall survival (OS) and breast cancer specific survival (BCSS) according to FBXO28 phosphorylation and expression level (Cohort 3, N = 498).

Table S6C. Cox univariate analysis for overall survival (OS) and breast-cancer specific survival (BCSS) according to FBXO28 phosphorylation and expression (Cohort 3, N = 498).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.